American College of Cardiology (ACC) Annual Scientific Sessions, New Orleans Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established atherosclerotic cardiovascular disease: Insights from the TECOS study
Jay Shavadia, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J. H. Cornel, Rury Holman, Eric D. Peterson
Journal of the American College of Cardiology 2019;73:9 (Suppl 1):138 [Abstract]
2018
European Society of Cardiology (ESC) Congress 2018, Munich LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS
G.M. De Ferrari, S.R. Stevens, G. Ambrosio, S. Leonard, D.K. McGuire, P.W. Armstrong, J.B. Green, M.A. Bethel, R.R. Holman, E.D. Peterson
European Heart Journal 2018;39:(Suppl 1):399-40 [Abstract]
American Diabetes Association (ADA) Conference, Orlando Cardiovascular Event Hazards over Time in TECOS
M. ANGELYN BETHEL, HARALD SOURIJ, SUSANNA R. STEVENS, YULIYA LOKHNYGINA, RENATO D. LOPES, AMANDA ADLER, DARREN K. MCGUIRE, ERIC PETERSON and RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):452-P [Abstract]
American Diabetes Association (ADA) Conference, Orlando Regional Variations in Case Fatality following a Major Coronary or Cerebrovascular Event in People with Type 2 Diabetes-Evidence from the ADVANCE Trial and TECOS Trial
PHILIP M. CLARKE, XINYANG HUA, JOHN CHALMERS, MARK WOODWARD, ESQ., RUTH L. COLEMAN, JENNIFER B. GREEN, DARREN K. MCGUIRE, RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):1299-P [Abstract]
2017
Diabetes UK Annual Professional Conference, Manchester Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)
S.S. Engel, M.A. Bethel, J. Garg, S.R. Stevens, Y. Lokhnygina3, R.G. Josse4, J.B. Green, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S3 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon No major impact seen with sitagliptin on rates of cardiovascular death or hospitalisation for heart failure following myocardial infarction during TECOS
M.A. Nauck, K.S. Pieper, Y. Lokhnygina, D.K. McGuire, E.D. Peterson, R.R. Holman,
Diabetelogia 2017;60:(Suppl 1):S356 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Association between race and glycaemic response to sitagliptin: insights from TECOS
T.M.E. Davis, H. Mulder, Y. Lokhnygina, E. Standl, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S356 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
A.M. Gray, J. Leal, S.D.Reed, Y. Li, F. Graham, J.B.Green, K.D. Kaufman, L. Radican, J. Alfredsson, J. Buse, A. Riefflin, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S357 [Abstract]
American Heart Association (AHA) Scientific Sessions 2017, Anaheim Underuse of Oral Anticoagulation, High Use of Aspirin and Worse Clinical Outcomes in Patients With Type 2 Diabetes and Atrial Fibrillation: Insights From the TECOS Trial
Patricia Guimaraes, Renato D Lopes, Susanna R Stevens, Jennifer B Green, Darren K McGuire, Rury R Holman and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;136:Supp 1: [Abstract]
American Heart Association (AHA) Scientific Sessions 2017, Anaheim International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS
Ankeet S Bhatt, Nancy Luo, Nicole Solomon, Neha J Pagidipati, Giuseppe Ambrosio, Jennifer B Green, Darren K McGuire, Eberhard Standl, Jan H Cornel, Sigrun Halvorsen, Renato D Lopes, Harvey White, Rury R Holman, Eric D Peterson, and Robert J Mentz, on behalf of the TECOS Study Group
Circulation 2017;136:Suppl 1: [Abstract]
Association of British Clinical Diabetologists (ABCD) Autumn Meeting 2016, Brighton Estimating the potential risk reduction of Type 2 diabetes mellitus (T2DM) complications if systolic blood pressure (SBP) targets were to be lowered
S Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman, MA Bethel
The British Journal of Diabetes 2017;17:1:42 [Abstract]
Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2017, Arlington Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3: [Abstract]
European Society of Cardiology (ESC) Congress 2017, Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial
Neha J Pagidipati, Ann Marie Navar, Karen S Pieper, Jennifer B Green, M. A Bethel, Paul W Armstrong, Robert G Josse, Darren K McGuire, Yuliya Lokhnygina, Jan H Cornel, Sigrun Halvorsen, Timo E Strandberg, Tuncay Delibasi, Rury R Holman, and Eric D Peterson, on behalf of the TECOS Study Group
Circulation 2017;10:Suppl 3: [Abstract]
Francophone Society of Diabetes Annual Congress 2017, Lille Evaluation of the Safety Profile of Sitagliptin in Older Adults in the TECOS Cardiovascular Safety Trial
Angelyn Bethel, Samuel Engel, Jennifer Green, Zhen Huang, Keith Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A55-A56
Francophone Society of Diabetes Annual Congress 2017, Lille Impact on cardiovascular events and tolerance of sitagliptin in insulin-treated patients with type 2 diabetes: the TECOS experiment
Angelyn Bethel, Sam Engel, Jie Ding, Robert Josse, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56
Francophone Society of Diabetes Annual Congress 2017, Lille Differences Between Men and Women in the Cardiovascular Safety Test of Sitagliptin (TECOS)
Jennifer Green, Joakim Alfredsson, Susanna Stevens, Shelby Reed, Darren McGuire, Paul Armstrong, Sam Engel, Angelyn Bethel, Frans Van de Werf, Eric Peterson, Rury Holman
Diabetes and Metabolism 2017;43:2 Suppl:A56
American Diabetes Association (ADA) Conference, San Diego-P Medical Resource Use and Costs in Patients with Type 2 Diabetes Mellitus during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D. REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M. GRAY, JOHN B. BUSE, JENNIFER B. GREEN, KEITH D. KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D. PETERSON, RURY R. HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):A697-A750. [Abstract]
American Diabetes Association (ADA) Conference, San Diego Time to Insulin in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M A BETHEL, SAMUEL S ENGEL, JYOTSNA GARG, SUSANNA R STEVENS, YULIYA LOKHNYGINA, ROBERT G JOSSE, JENNIFER B GREEN, ERIC D PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2017;66:(Suppl 1):1183-P [Abstract]
American Diabetes Association (ADA) Conference, San Diego Emerging Sitagliptin Benefit for All-Cause Hospitalizations: Evidence from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SHELBY D REED, YANHONG LI, JOSE LEAL, FELICIA GRAHAM, JOAKIM ALFREDSSON, ALASTAIR M GRAY, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, AXEL RIEFFLIN, SHAILAJA SURYAWANSHI, FRANS VAN DE WERF, ERIC D PETERSON, RURY R HOLMAN, FOR THE TECOS STUDY
Diabetes 2017;66:(Suppl 1):1344-P
2016
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial
R.G. Josse, S.R. Majumdar, Y. Zheng, J.B. Buse, J.B. Green, K.D. Kaufman, E.D. Peterson, R.R.Holman, P.W. Armstrong, on behalf of the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S372 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience
M.A. Bethel, S.S. Engel, J. Ding, R.G. Josse, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S369 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabete, Munich Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
S.S. Engel, S. Suryawanshi, R.G. Josse, E.D. Peterson, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S361 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
J.B. Green, J. Alfredsson, S.R. Stevens, S.D. Reed, D.K. McGuire, P.W. Armstrong, S.S. Engel, M.A. Bethel, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetologia 2016;59:Suppl 1:S544 [Abstract]
American Heart Association (AHA) Scientific Sessions 2016, New Orleans Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial
Ann M Navar, Dianne S Gallup, Yuliya Lokhnygina, Jennifer B Green, Darren K McGuire, Paul W Armstrong, John B Buse, Samuel S Engel, John M Lachin, Eberhard Standl, Frans Van de Werf, Rury R Holman, and Eric D Peterson
Circulation 2016;134:Suppl 1: [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin
MA Bethel, SS Engel, JB Green, Z Huang, KD Kaufman,E Standl, S Suryawanshi, F Van de Werf, ED Peterson, and RR Holman
Diabetic Medicine 2016;33:Suppl 1:86 [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Assessing the Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SAMUEL S ENGEL, SHAILAJA SURYAWANSHI, ROBERT G JOSSE, ERIC PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):1181-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
ROBERT G JOSSE, SUMIT R MAJUMDAR, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, CYNTHIA M WESTERHOUT, YINGGAN ZHENG, ERIC PETERSON, RURY R HOLMAN, PAUL W ARMSTRONG, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):587-P [Abstract]
2009
69th Scientific Session of the American Diabetes Association, New Orleans Rationale and Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Bethel MA, Green J, Califf RM, Holman RR
Diabetes 2009;59:Suppl 1:A555 [Abstract]
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857240 Email: dtu@dtu.ox.ac.uk
